IMPACT FACTOR 5.863 an Open Access Journal by MDPI The Future Direction of Radiopharmaceutical Development for Cancer Theranostics Guest Editor: Message from the Guest Editor Dr. Martina Benešová Dear Colleagues Research Group Molecular Biology of Systemic The journal Pharmaceuticals is planning to publish a Radiotherapy, Research Program Special Issue covering the topic “The Future Direction of Imaging and Radiooncology, German Cancer Research Center Radiopharmaceutical Development for Cancer (DKFZ), Im Neuenheimer Feld Theranostics”, and I am cordially inviting you to contribute 223, D-69120 Heidelberg, an article to this volume. Germany. [email protected] The purpose of this Special Issue is to host research and review papers on the development of novel radiopharmaceuticals and therapy strategies for cancer theranostics, which hold a great promise for improved Deadline for manuscript patients’ outcomes in the future. Areas of interest include, submissions: closed (31 January 2020) but are not limited to: Identification of new targets for cancer theranostics; Design of novel radiopharmaceuticals for cancer theranostics; Evaluation of non-standard radionuclides potentially suitable for cancer theranostics; Experimental targeted radionuclide therapy strategies; Prospective combination therapy with targeted radionuclide therapy involved. mdpi.com/si/28102 SpeciaIslsue IMPACT FACTOR 5.863 an Open Access Journal by MDPI Editor-in-Chief Message from the Editor-in-Chief Dr. Jean Jacques Vanden Because of your expertise in the field of drug sciences, I Eynde kindly invite you to consider publishing your current work, Formerly head of the Department in the form of a research article or a review, in the open of Organic Chemistry (FS), University of Mons-UMONS, 7000 access electronic journal Pharmaceuticals. Mons, Belgium Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer- reviewed and a final decision is provided to authors within 4–6 weeks aer submission. Papers are published on the web immediately aer acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to Pharmaceuticals soon. Author Benefits Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions. High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and many other databases. Journal Rank: JCR - Q1 (Pharmacology & Pharmacy) / CiteScore - Q2 (Pharmaceutical Science) Contact Us Pharmaceuticals Tel: +41 61 683 77 34 mdpi.com/journal/pharmaceuticals MDPI, St. Alban-Anlage 66 Fax: +41 61 302 89 18 [email protected] 4052 Basel, Switzerland www.mdpi.com.